325 Results

People

  1. Lacouture
    Lacouture
  2. Kris
    Kris
  3. Hudis
    Hudis
  4. Motzer
    Motzer
  5. Saltz
    Saltz
  6. Seidman
    Seidman
  7. Heelan
    Heelan
  8. Kelsen
    Kelsen
  9. Ilson
    Ilson
  10. Norton
    Norton

Groups

  1. Department of Medicine (244)
  2. Solid Tumor Oncology Division (195)
  3. Survivorship Research (84)
  4. Gastrointestinal Oncology Service (57)
  5. Breast Medicine Service (46)
  6. Division of Subspecialty Medicine (45)
  7. Dermatology Service (41)
  8. Dermatology (41)
  9. Hematologic Malignancies, Division of (36)
  10. Surgery (34)
  1. "alopecia"
Formats
  1. Journal Article (301)
  2. Review (14)
  3. Conference Paper (5)
  4. Research Letter (3)
  5. Editorial (1)
  6. Guidelines (1)
Groups
  1. Department of Medicine (244)
  2. Solid Tumor Oncology Division (195)
  3. Survivorship Research (84)
  4. Gastrointestinal Oncology Service (57)
  5. Breast Medicine Service (46)
  6. Division of Subspecialty Medicine (45)

More Groups

People
  1. Mario Lacouture (38)
  2. Mark Kris (20)
  3. Clifford Hudis (15)
  4. Andrew Seidman (14)
  5. Leonard Saltz (14)
  6. Robert Motzer (14)

More People

Years
  1. 2025 (7)
  2. 2024 (20)
  3. 2023 (16)
  4. 2022 (11)
  5. 2021 (11)
  6. 2020 (14)

More Years

Publications
  1. Journal of Clinical Oncology (33)
  2. Cancer (14)
  3. Lancet Oncology (13)
  4. Clinical Cancer Research (12)
  5. Investigational New Drugs (11)
  6. Gynecologic Oncology (10)

More Publications

Publishers
  1. Elsevier Inc. (52)
  2. American Society of Clinical Oncology (35)
  3. Springer (31)
  4. Elsevier Science, Inc. (20)
  5. Wiley Blackwell (20)
  6. Oxford University Press (19)

More Publishers

Results (325)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Validation and responsiveness of the English version of the Chemotherapy-Induced Alopecia Distress Scale (CADS) in breast cancer patients
    Journal Article

    Kraehenbuehl, L.; Kang, D.; Bang, A. S.; Ketosugbo, K. F.; Hay, J.; Patil, S.; Goldfarb, S.; Cho, J.; Lacouture, M. E.
    Supportive Care in Cancer (2024)

    Fulltext@MSK | Save
  • Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer
    Review

    Brower, B.; McCoy, A.; Ahmad, H.; Eitman, C.; Bowman, I. A.; Rembisz, J.; Milowsky, M. I.
    Frontiers in Oncology (2024)

    Fulltext@MSK | Save
  • Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
    Journal Article

    Epstein-Peterson, Z. D.; Drill, E.; Aypar, U.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamlin, P. A.; Ho, C.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Analysis of East Asia subgroup in Study 309/KEYNOTE-775: Lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer
    Journal Article

    Yonemori, K.; Fujiwara, K.; Hasegawa, K.; Yunokawa, M.; Ushijima, K.; Suzuki, S.; Shikama, A.; Minobe, S.; Usami, T.; Kim, J. W.; more...
    Journal of Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104)
    Journal Article

    Ho, A. L.; Foster, N. R.; Deraje Vasudeva, S.; Katabi, N.; Antonescu, C. R.; Frenette, G. P.; Pfister, D. G.; Erlichman, C.; Schwartz, G. K.
    Cancer (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)
    Journal Article

    Lumish, M.; Chui, M. H.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Cohen, S.; Friedman, C.; Grisham, R.; Konner, J.; Kyi, C.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Oncology for the rhinologist
    Review

    Tam, K.; Dunn, L. A.; Cohen, M. A.
    Current Opinion in Otolaryngology & Head and Neck Surgery (2024)

    Fulltext@MSK | Save
  • EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
    Journal Article

    Rosenberg, J. E.; Powles, T.; Sonpavde, G. P.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; Castellano, D.; Mamtani, R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Safety of immunomodulatory systemic therapies used in the management of immune-related cutaneous adverse events
    Review

    Gu, S. L.; Nath, S.; Markova, A.
    Pharmaceuticals (2023)

    Fulltext@MSK | Save
  • The role of dermocosmetics in the management of cancer-related skin toxicities: International expert consensus
    Review

    Dreno, B.; Khosrotehrani, K.; De Barros Silva, G.; Wolf, J. R.; Kerob, D.; Trombetta, M.; Atenguena, E.; Dielenseger, P.; Pan, M.; Scotte, F.; more...
    Supportive Care in Cancer (2023)

    Fulltext@MSK | Save